» Articles » PMID: 2407301

N-ras Gene Point Mutations in Childhood Acute Lymphocytic Leukemia Correlate with a Poor Prognosis

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 1990 Mar 1
PMID 2407301
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Ras genes can be altered by point mutations at critical portions of their coding regions to acquire transforming ability in vitro. These point mutations have been detected in a variety of human malignancies. However, their relevance for the clinical and biologic behavior of the subgroups of patients exhibiting these mutations in unclear. We analyzed 100 patients with childhood acute lymphocytic leukemias (ALLs) for point mutations of exons 1 and 2 of all three ras genes (H-ras, K-ras, and N-ras) by polymerase chain reaction and a combination of oligonucleotide hybridization and direct DNA sequencing. A 6% incidence of N-ras gene mutations was detected, all of which occurred at different nucleotides of codons 12 or 13 of N-ras. When correlating presence of ras mutations with the clinical and biologic features and the clinical outcome of these cases, a significantly higher risk for hematologic relapse (P = .01) and a trend toward a lower rate of complete remission (P = .07) was noted. The two groups did not differ in any of the known high-risk factors of ALL. These results suggest that presence of an N-ras mutation in children with ALL may be an independent predictor for worse clinical outcome and therefore may have therapeutic implications; further studies to confirm these findings are required because of the small number of patients with N-ras mutations.

Citing Articles

Detection of gene mutation and its clinical significance in children with acute lymphoblastic leukemia.

Yao Y, Wang X, Zhao X, Li S, Zhou Y, Xu Y Zhongguo Dang Dai Er Ke Za Zhi. 2022; 24(3):309-313.

PMID: 35351263 PMC: 8974658. DOI: 10.7499/j.issn.1008-8830.2109141.


Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic Targeting.

Knight T, Irving J Front Oncol. 2014; 4:160.

PMID: 25009801 PMC: 4067595. DOI: 10.3389/fonc.2014.00160.


Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants.

Driessen E, Van Roon E, Spijkers-Hagelstein J, Schneider P, De Lorenzo P, Valsecchi M Haematologica. 2013; 98(6):937-44.

PMID: 23403319 PMC: 3669451. DOI: 10.3324/haematol.2012.067983.


Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL.

Tzoneva G, Perez-Garcia A, Carpenter Z, Khiabanian H, Tosello V, Allegretta M Nat Med. 2013; 19(3):368-71.

PMID: 23377281 PMC: 3594483. DOI: 10.1038/nm.3078.


Prognostic Significance of NRAS Gene Mutations in Children with Acute Myelogenous Leukemia.

Aly R, El-sharnoby M, Hagag A Mediterr J Hematol Infect Dis. 2012; 3(1):e2011055.

PMID: 22220252 PMC: 3248332. DOI: 10.4084/MJHID.2011.055.